Piramal buys Bayers potential Alzheimer drug

Drugmaker Piramal Healthcare has agreed to buy a research and development portfolio from Bayer AG, the company said, in a deal that gives Piramal rights to florbetaben, a possible Alzheimer treatment.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money Realasset
moneycontrol.com

Home » News » Business

Apr 16, 2012, 01.45 PM | Source: Reuters

Piramal buys Bayer's potential Alzheimer drug

Drugmaker Piramal Healthcare has agreed to buy a research and development portfolio from Bayer AG, the company said, in a deal that gives Piramal rights to florbetaben, a possible Alzheimer treatment.

Like this story, share it with millions of investors on M3

Piramal buys Bayers potential Alzheimer drug

Drugmaker Piramal Healthcare has agreed to buy a research and development portfolio from Bayer AG, the company said, in a deal that gives Piramal rights to florbetaben, a possible Alzheimer treatment.

Post Your Comments

Share Cancel

Piramal buys Bayers potential Alzheimer drug
Drugmaker Piramal Healthcare has agreed to buy a research and development portfolio from Bayer AG, the company said, in a deal that gives Piramal rights to florbetaben, a possible Alzheimer treatment.

Florbetaben, which is in the final stages of clinical trials, works by detecting symptoms in probable sufferers of Alzheimer's, and is expected to allow earlier detection and specific treatment of the disease, Piramal said in a statement.

Florbetaben is racing with similar Alzheimer's imaging agents from global pharmaceutical companies such as Eli Lilly and Co, Pfizer Inc and General Electric Co to enter a global market estimated at anywhere from USD 1 billion to USD 5 billion.

Piramal will acquire intellectual property, worldwide development, marketing and distribution rights of florbetaben and other clinical and pre-clinical assets of Bayer's molecular imaging business in the deal. Financial aspects of the deal were not available.

"We plan to build a promising portfolio in the pharma space, including our newly acquired molecular imaging assets, which will help us create a global branded pharma business," Ajay Piramal, chairman of the Piramal Group, was quoted as saying.

Piramal Enter stock price

On May 31, 2016, Piramal Enterprises closed at Rs 1442.00, up Rs 57.05, or 4.12 percent. The 52-week high of the share was Rs 1536.50 and the 52-week low was Rs 805.00.


The company's trailing 12-month (TTM) EPS was at Rs 61.49 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 23.45. The latest book value of the company is Rs 724.84 per share. At current value, the price-to-book value of the company is 1.99.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Piramal buys Bayers potential Alzheimer drug

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login